Secondary prophylaxis of venous thromboembolism

Vasa - Journal of Vascular Diseases

Volumn 34, Issue 1, 2005, Pages 3-10

  Schellong, Sebastian M ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Bleeding risk; Recurence; Thrombophilia; Venous thromboembolism; Vitamin K antagonists

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; ANTIVITAMIN K; DALTEPARIN; HEPARIN; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; PLACEBO; PROTEIN C; PROTEIN S; TINZAPARIN; XIMELAGATRAN;

ANTIPHOSPHOLIPID SYNDROME; ANTITHROMBIN DEFICIENCY; BLEEDING TENDENCY; CANCER PATIENT; CLINICAL TRIAL; COMORBIDITY; DRUG CHOICE; DRUG COST; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG SAFETY; HIGH RISK POPULATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER TOXICITY; LONG TERM CARE; LUNG EMBOLISM; MEDICAL DECISION MAKING; META ANALYSIS; PRESCRIPTION; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RECURRENT DISEASE; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SECONDARY PREVENTION; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; THROMBOPHILIA; TREATMENT PLANNING; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; COMORBIDITY; HEMORRHAGE; HUMANS; PULMONARY EMBOLISM; RECURRENCE; RISK FACTORS; THROMBOPHILIA; VENOUS THROMBOSIS; VITAMIN K;

EID: 14644411071     PISSN: 03011526     EISSN: None     Source Type: Journal    
DOI: 10.1024/0301-1526.34.1.3     Document Type: Review

References (59)

1. CARS Study Investigators. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction: Coumadin Aspirin Reinfarction Study. Lancet 1997; 350: 389-96.
2. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: Randomised trial of low intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention in ischemic heart disease in men at increased risk. Lancet 1998; 351: 233-41.
3. Agnelli G. Long-term low-dose warfarin use is effective in the prevention of recurrent venous thromboembolism: no. J Thromb Haemost 2004; 2: 1038-40.
4. Agnelli G, Prandoni P, Becattini C, Silingardi M, Taliani MR, Miccio M, Imberti D, Poggio R, Ageno W, Pogliani E, Porro F, Zonzin P. Investigators WODIT. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 2003; 139: 19-25.
5. Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, Moia M, Guazzaloca G, Bertoldi A, Tomasi C, Scannapieco G, Ascani A, Villalta S, Frulla M, Mosena L, Girolami A, Vaccarino A, Alatri A, Palareti G, Marchesi M, Ambrosio GB, Parisi R, Doria S, Steidl L, Ambrosini F, Silingardi M, Ghirarduzzi A, Iori I, Ageno W, the Warfarin Optimal Duration Italian Trial Investigators. Three Months versus One Year of Oral Anticoagulant Therapy for Idiopathic Deep Venous Thrombosis. N Engl J Med 2001; 345: 165-9.
6. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003;362:523-36.
7. Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism. Lancet 1960: 1309-12.
8. Bernardi E, Piccioli A, Oliboni G, Ziun R, Girolami A, Prandoni P. Nomograms for the administration of unfractionated heparin in the initial treatment of acute thromboembolism - an overview. Thromb Haemost 2000; 84: 22-6.
9. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105: 91-9.
10. Brandjes DP, Heijboer H, Buller HR, de Rijk M, Jagt H, ten Cate JW. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992; 327: 1485-9.
11. Büller HR, Cohen AT, Lensing AWA, Monreal M, Prins MH, Schulman S, Lassen MR, van Amsterdam RGM. A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. J Thromb Haemost 2004; 2: 47-53.
12. Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, Segers AEM, Cariou R, Leeuwenkamp O, Lensing AWA. Fondaparinux or Enoxaparin for the initial treatment of symptomatic deep venous thrombosis. Ann Int Med 2004; 140: 867-73.
13. Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, Segers AEM, Cariou R, Leeuwenkamp O, Lensing AWA. Subcutaneous Fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2004; 349: 1695-702.
14. Crowther MA, Ginsberg JS, Julian J, Math M, Denburg J, Hirsh J, Douketis J, Laskin C, Fortin P, Anderson D, Kearon C, Clarke A, Geerts W, Forgie M, Green D, Costantini L, Yacura W, Wilson S, Gent M, Kovacs MJ. A Comparison of Two Intensities of Warfarin for the Prevention of Recurrent Thrombosis in Patients with the Antiphospholipid Antibody Syndrome. N Engl J Med 2003; 349: 1133-8.
15. De Stefano V, Martinelli I, Mannucci PM, Paciaroni K, Chiusolo P, Casorelli I, Rossi E, Leone G. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A transition in the prothrombin gene. N Engl J Med 1999; 341: 801-6.
16. Douketis JD. Perioperative anticoagulation management in patients who are receiving oral anticoagulant therapy: a practical guide for clinicians. Thromb Res 2003; 108: 3-13.
17. Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS. Risk of Fatal Pulmonary Embolism in Patients With Treated Venous Thromboembolism. JAMA 1998; 279: 458-62.
18. Dunn AS, Turpie AG. Perioperative management of patients receiving oral anticoagulants: a systematic review. Arch Intern Med 2003; 163: 901-8.
19. Eichinger S, Minar E, Bialonczyk C, Hirschl M, Quehenberger P, Schneider B, Weltermann A, Wagner O, Kyrle PA. D-dimer levels and risk of recurrent venous thromboembolism. JAMA 2003;290:1071-4.
20. Eichinger S, Stumpflen A, Hirschl M, Bialonczyk C, Herkner K, Stain M, Schneider B, Pabinger I, Lechner K, Kyrle PA. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost 1998; 80: 566-9.
21. Eichinger S, Weltermann A, Minar E, Stain M, Schonauer V, Schneider B, Kyrle PA. Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism. Arch Intern Med 2004; 164: 92-6.
22. Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation clinics. Ann Intern Med 1996; 124: 970-9.
23. Hansson PO, Sörbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 2000; 160: 769-74.
24. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJr. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000; 160: 761-8.
25. Huisman MVobotTI. Efficacy and safety of the oral direct thrombin inhibitor ximelagatan compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: a randomized, double-blind, multinational study. J Thromb Haemost 2003; 1 (Suppl): Abstract OC003.
26. Hull R, Hirsh J, Jay R, Carter C, England C, Gent M, Turpie AG, McLoughlin D, Dodd P, Thomas M, Raskob G, Ockelford P. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982; 307: 1676-81.
27. Hull RD, Raskob GE, Brant RF, Pineo GF, Valentine KA. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med 1997; 157: 2562-8.
28. Hull RD, Raskob GE, Pineo GF, Grren D, Trowbridge AA, Elliott GG, Lerner RG, Hall J, Sparling T, Brettell HR, Norton J, Carter CJ, Geroge R, Merli G, Ward J, Mayo W, Rosenbloom D, Brand R. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975-82.
29. Hyers TM. Management of Venous Thromboembolism. Arch Intern Med 2003; 163: 759-68.
30. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996; 335: 540-6.
31. Iorio A, Guercini F, Pini M. Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants. J Thromb Haemost 2003; 1: 1906-13.
32. Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, Turpie AG, Green D, Ginsberg JS, Wells P, MacKinnon B, Julian JA, Johnston M, Douketis J, Roberts R, van Nguyen P, Kassis J, Dolan S, Demers C, Desjardins L, Solymoss S, Trowbridge A. A Comparison of Three Months of Anticoagulation with Extended Anticoagulation for a First Episode of Idiopathic Venous Thromboembolism. N Engl J Med 1999; 340: 901-7.
33. Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA, MacKinnon B, Weitz JI, Crowther MA, Dolan S, Turpie AG, Geerts W, Solymoss S, van Nguyen P, Demers C, Kahn SR, Kassis J, Rodger M, Hambleton J, Gent M. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349: 631-9.
34. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993-7.
35. Kovacs MJ. Long-term low-dose warfarin use is effective in the prevention of recurrent venous thromboembolism: no. J Thromb Haemost 2004; 2: 1041-3.
36. Kyrle PA, Eichinger S. The risk of recurrent venous thromboembolism. Vasa 2002; 31: 163-6.
37. Kyrle PA, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Eichinger S. The risk of recurrent venous thromboembolism in men and women. N Engl J Med 2004; 350: 2558-63.
38. Kyrle PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B, Weltermann A, Speiser W, Lechner K, Eichinger S. High Plasma Levels of Factor VIII and the Risk of Recurrent Venous Thromboembolism. N Engl J Med 2000; 343: 457-62.
39. Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, rickles R, Julian JA, Haley S, Kovacs MJ, Gent M. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-53.
40. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest 2001; 119: 108S-21S.
41. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003; 139: 893-900.
42. McMahan DA, Smith DM, Carey MA, Zhou XH. Risk of major hemorrhage for outpatients treated with warfarin. J Gen Intern Med 1998; 13: 311-6.
43. Murin S, Romano PS, White RH. Comparison of outcomes after hospitalization for deep venous thrombosis or pulmonary embolism. Thromb Haemost 2002; 88: 407-14.
44. Palareti G, Legnani C, Cosi B, Valdró L, Lunghi B, Bernardi F, Coccheri S. Predictive Value of D-Dimer Test for Recurrent Venous Thromboembolism After Anticoagulation Withdrawal in Subjects With a Previous Idiopathic Event and in Carriers of Congenital Thrombophilia. Circulation 2003; 108: 313-8.
45. Pinede L, Ninet J, Duhaut P, Chabaud S, Demolombe-Rague S, Durieu I, Nony P, Sanson C, Boissel JP. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 2001; 103: 2453-60.
46. Pineo GF, Hull RD. Tinzaparin in the treatment of venous thromboembolism. Expert Opin Pharmacother 2003; 4: 2355-62.
47. Piovella F, Crippa L, Barone M, Vigano D'Angelo S, S. S, Galli L, Beltramett C, D'Angelo A. Normalization rates of compression ultrasonography in patients with a first episode of deep vein thrombosis of the lower limbs: association with recurrence and new thrombosis. Haematologica 2002; 87: 515-22.
48. Prandoni P, Lensing AW, Bagatella P, Simioni P, Girolami A. Low rate of warfarin-related major bleeding in patients with recurrent venous thromboembolism [letter]. Thromb Haemost 1999; 82: 158-9.
49. Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, Cattelan AM, Polistena P, Bernardi E, Prins MH. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7.
50. Prandoni P, Lensing AW, Prins MH, Bernardi E, Marchiori A, Bagatella P, Frulla M, Mosena L, Tormene D, Piccioli A, Simioni P, Girolami A. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002; 137: 955-60.
51. Ridker PM. Long-term low-dose warfarin use is effective in the prevention of recurrent venous thromboembolism: yes. J Thromb Haemost 2004; 2: 1034-7.
52. Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, Cushman M, Moll S, Kessler CM, Elliott CG, Paulson R, Wong T, Bauer KA, Schwartz BA, Miletich JP, Bounameaux H, Glynn RJ. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003; 348: 1425-34.
53. Schulman S, Granqvist S, Holmstrom M, Carlsson A, Lindmarker P, Nicol P, Eklund S-G, Nordlander S, Larfars G, Leijd B, Linder O, Loogna E, Walter H, Viering S, Hjorth M, Boberg J, The Duration of Anticoagulation Trial Study Group. The Duration of Oral Anticoagulant Therapy after a Second Episode of Venous Thromboembolism. N Engl J Med 1997; 336: 393-8.
54. Schulman S, Rhedin A-S, Lindmarker P, Carlsson A, Larfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter H, Viering S, Nordlander S, Leijd B, Jonsson K-A, Hjorth M, Linder O, Boberg J, The Duration of Anticoagulation Trial Study Group. A Comparison of Six Weeks with Six Months of Oral Anticoagulant Therapy after a First Episode of Venous Thromboembolism. N Engl J Med 1995; 332: 1661-5.
55. Schulman S, Wählander K, Lundström t, Clason SB, Eriksson H. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor Ximelagatran. N Engl J Med 2003; 349: 1713-21.
56. van den Belt AG, Prins MH, Lensing AW, Castro AA, Clark OA, Atallah AN, Burihan E. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2000: CD001100.
57. van der Heijden JF, Hutten BA, Buller HR, Prins MH. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Database Syst Rev 2002: CD002001.
58. van der Meer J, Rosendaal FR, Vandenbroucke JP, Brier E. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Ann Intern Med 1993; 153: 1557-62.
59. Weltermann A, Eichinger S, Bialonczyk C, Minar E, Hirschl M, Quehenberger P, Schonauer V, Kyrle PA. The risk of recurrent venous thromboembolism among patients with high factor IX levels. J Thromb Haemost 2003; 1: 28-32.